MDNA Moves Into Liquid Biopsy Market With New Prostate Cancer Test

Dec 02, 2016

|

Premium

NEW YORK (GenomeWeb) – Mitochondrial DNA diagnostics firm MDNA Life Sciences announced the launch of its first noninvasive blood-based cancer test this week, with Phi Life Sciences as the assay's first US distributor.

Though the company got its start developing assays for analysis of tissue samples, researchers have more recently found that the firm's mitochondrial DNA-based approach is similarly sensitive when applied to blood samples. Based on this, the company has now shifted its focus to the liquid biopsy space.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

Featured White Papers

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

Apr

23

Featured Webinar

AMP/ACMG/CAP Cancer Sequence Variant Guidelines: A Two-Year Status Report

In 2016, the Association for Molecular Pathology (AMP), in partnership with the College of American Pathologists (CAP) and American College of Molecular Genetics (ACMG), launched a set of guidelines meant to set industry standards for reporting of molecular diagnostic test results in oncology, using a tier-based system and defined levels of evidence.

Apr

24

Featured Webinar

Metabolomics Analyses to Elucidate Systemic Processes in Human Health and Disease

This webinar will provide a wide-ranging overview of the promise for metabolomics in studying human health and disease, as well as its potential for integration with other -omics disciplines.

Apr

30

Featured Webinar

Novel Methods for Improving De Novo Transcriptome Annotation with Long-Read Transcript Sequencing

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May

08

Featured Webinar

OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Melanoma and Pancreatic Cancer

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

Menu